# Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

> **NCT04196231** · PHASE4 · COMPLETED · sponsor: **University of Campania Luigi Vanvitelli** · enrollment: 258 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** IDegLira
- **DRUG:** IGlarLixi
- **DRUG:** Insulin/Canaglifozin
- **DRUG:** Insulin/Dapaglifozin
- **DRUG:** Insulin/Empaglifozin
- **DRUG:** Basal Bolus

## Key facts

- **NCT ID:** NCT04196231
- **Lead sponsor:** University of Campania Luigi Vanvitelli
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-27
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-10-20
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196231, "Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04196231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*